Recursion Pharmaceuticals - Class A opened lower at $3.44, compared with its previous close of $3.59. In the last trading session, the stock traded between $3.27 and $3.46. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Recursion Pharmaceuticals - Class A is now worth
$ 18.67
Resulting in a loss of
$ 81.33 (81.33%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.27 (-7.38%)
Day High
$3.46
Day Low
$3.27
Day Open
$3.44
Prev Close
$3.59
Volume
1,84,43,406
1W Return
-13.97%
1M Return
-16.98%
3M Return
-0.60%
6M Return
1.99%
1Y Return
-29.41%
Market Cap ($ Mn)
2,071
PE Ratio
-
PB Ratio
1.94
PEG Ratio
-
ROE
-63.64%
ROCE
-54.28%
EPS (TTM)
$-0.21
1 Week
-13.97%
1 Month
-16.98%
3 Months
-0.60%
6 Months
1.99%
9 Months
-10.38%
Recursion Q3FY26 Results: Net loss narrows 27% YoY to $119.0 million
Net loss narrowed 27% YoY to $119.0 million in Q3FY26. Total revenue rose to $18.6 million, driven by a $10.0 million Sanofi milestone. Cash runway extended into 2029 with pro forma cash of $748.7 million. Positive Phase 2 data reported for REC-4881 in FAP patients. Fred Hassan appointed as Chair of the Board effective October 31, 2026.
10 days agoRecursion posts 47% median polyp reduction in Phase 2 FAP trial
REC-4881 achieved a **47% median reduction** in total polyp burden in Phase 2 FAP trial. 85% of evaluable patients remained below baseline polyp burden 12 weeks post-treatment. Two patients achieved ≥98% reductions in upper GI polyp burden. Registrational trial initiation targeted for second half of 2027.
10 days agoRecursion appoints Fred Hassan as board chair effective Oct 31
Fred Hassan appointed as Chair of the Board. Appointment effective October 31, 2026. Company focuses on AI-enabled drug discovery.
10 days agoRecursion raises $200 million, extends cash runway into 2029
Raised $200 million via underwritten offering at $3.25 per share. Cash runway extended into 2029, supporting clinical trials through 2027. Sanofi exercised option on first development candidate, triggering $10 million milestone. Shares rose 0.24% after hours following the offering announcement.
28 days agoRecursion Pharmaceuticals Q2 2026 Results: OPEX guidance cut 40% to $375 million
Recursion cuts 2026 cash operating expense guidance to $375 million, down nearly 40% from 2024. Company holds $557 million in cash, providing an operational runway through early 2028. Partnership inflows exceed $500 million, including $216 million from Roche/Genentech. REC 4881 shows 43% median polyp burden reduction in FAP Phase 2 trial. FDA clears IND for REC 7735, a selective PI3 kinase inhibitor for solid tumors.
1mo agoRecursion grants 3.2M RSUs to 24 new hires under Nasdaq inducement rules
Recursion granted 3,234,866 Class A RSUs to 24 new employees on July 27, 2026, under its 2024 Inducement Equity Incentive Plan. The awards comply with Nasdaq Listing Rule 5635(c)(4) and vest over four years, starting with a one-year cliff. This strategic hiring move supports the company's AI-native drug discovery platform.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Recursion Pharmaceuticals - Class A is now worth
$ 18.67
Resulting in a loss of
$ 81.33 (81.33%)
Note: Past profits do not guarantee future returns.
